Advances in genomics and cancer biology will alter the design of human cancer studies.
Critic At Large
Most Recent
Twenty-first century lab reports will include test results read by a new breed of pathologist.
A global R&D treaty could boost innovation and improve the health of the world’s poor—and rich.
Dietary supplements can have serious side effects when mixed with prescription drugs, but not all herb-drug interactions are bad.
Plant research remains grossly underfunded, despite the demand for increased crop production to support a growing population.
As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?
Low-dose antibiotics in animal feed fuel drug-resistance in human infectious diseases.
Twenty-first century challenges to the public health of all the world’s populations require forward-looking commitments from epidemiologists.
Ascribing benefits to the experience of devastating illness or trauma is fraught with hidden dangers.
Subjects
- culture
- disease/medicine
- funding
- opinion
- policy
- public health
- regulation
- science policy
- science publishing
- techniques
Sub Categories
- Bio Business
- Capsule Reviews
- Careers
- Contributors
- Critic At Large
- Editorial
- Features
- Foundations
- Lab Tools
- Modus Operandi
- Notebook
- Profile
- Reading Frames
- Scientist to Watch
- Speaking of Science
- The Literature
- Thought Experiment
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
